Abstract submission

GUIDELINES for abstract submission.

Abstract Structure

Abstracts should be no longer than one A4 page in portrait layout.
The title of the abstract should be as concise as possible and should appear in bold, lower case and in centre.
Co-authors and affiliations below the title in italics (the main author’s name should be underlined, and the name of the presenting author should be marked with an asterisk (*).

Abstract must be written in English and content should have a maximum of 300 words.
Main body of text to be left aligned.
Single spacing throughout.

References, denoted by superscript numbers in the text, should be listed at the end of the text using standard Chemical Abstracts Source Service Index terminology followed by YEAR, VOLUME, and PAGE
The use of figures, graphs and schemes is recommended where this aids the understanding of the text
Abstracts should be sent as an MS Word or PDF email attachment to Conference mail id with the subject line ‘CONFERENCE NAME abstract’ or you can submit online via the conference website.
Please include your full address and contact details of the main author and the presenting author in the email and indicate whether you are submitting an oral or a poster presentation.


Please note there is a 1MB limit for online abstract submission. If your abstract is larger, reduce the file size of your document by compressing the images. If the file size is still greater than 1MB please email without the attachment and we will reply with an email address to which you will be able to send the abstract.

After completion of conference, speakers could submit their full length papers to any of our related journals and will be published within 2 months of time period.

A confirmation mail will be sent in regards of receiving your abstract and if no mail has been received within one week, please contact the conference coordinator.


Indicate the purpose and objective of the research, the hypothesis that was tested or a description of the problem being analysed or evaluated.


Describe the study period / setting / location, study design, study population, data collection and methods of analysis used.


Present as clearly and in as much detail as possible the findings / outcome of the study. Please summarize any specific results.


Explain the significance of your findings / outcomes of the study for HIV prevention, treatment, care and / or support, and future implications of the results

The following review criteria will be used in scrolling abstracts submitted under option1:
– Is there a clear background and justified objective?
– Is the methodology/study design appropriate for the objectives?
– Are the results important and clearly presented?
– Are the conclusions supported by the results?
– Is the study original, and does it contribute to the field?

Abstract topics

Multiple sclerosis and related disorders case reports/ case series or research / audits

1. Difficulty in diagnosing inflammatory demyelinating disorders
2. Variable presentation of subtypes
3. Patient reported outcomes
4. Neuro-ophthalmology
5. Treatment responses & Outcomes

Pathology and pathogenesis of multiple sclerosis and NMOSD research  

6. Pathology /Genetics/ Epigenetics
7. Immunology
8. Neurodegeneration
9. MRI and PET
10. OCT
11.  Neuropsychology
13. Biomarker 

Outcome measures research and audits

14. Immunomodulation/ Immunosuppression
15. Long-term treatment
16. monitoring
17. Risk management for disease modifying treatments
18. Tools for detecting therapeutic response
19. Symptomatic treatment


All submitted abstracts will go through a peer review process carried out by a peer review committee. After successful review of your abstract, we will guide you further steps towards your presence at our event.